Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
about
Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literaturePotential Clinical and Economic Impact of Switching Branded Medications to Generics.Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs.Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective StudyThe introduction of generic risperidone in Medicare Part DDrug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.Switching from brand-name to generic psychotropic medications: a literature review.What do prescribers think of biosimilars?Generic formulations of psychotropic medications and treatment responseMixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
P2860
Q26749431-1C9DE39C-3510-4854-9164-2B7D35AEB3B8Q33637817-09EC8467-6C98-4756-8872-D05D23F061FFQ35008178-11A4755B-F3D1-4F47-8D1D-764E2E869692Q35012595-D9B69591-029F-4994-B590-83432BC5BA67Q35965576-543EE66D-4736-405A-9FE8-8A73C52A690BQ37024443-5952960B-624B-4F0F-A607-E1AE03BF3543Q37574860-18CF19A4-42CA-4E1C-B1B9-B3547C5B73F1Q37813190-02FBC0C9-4F02-4C89-B54D-50D2D88DB207Q37977012-76044099-2966-46B8-8C21-96B935D2ED64Q42293277-D04BA0B0-4721-4798-B1C3-F6753D899B37Q47381084-167C0604-EF16-492F-A783-44F463034569Q52664925-4AE18ACA-5FA3-4EF0-948C-5B8581DD974E
P2860
Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Loss of response after switchi ...... considerations when switching.
@en
Loss of response after switchi ...... considerations when switching.
@nl
type
label
Loss of response after switchi ...... considerations when switching.
@en
Loss of response after switchi ...... considerations when switching.
@nl
prefLabel
Loss of response after switchi ...... considerations when switching.
@en
Loss of response after switchi ...... considerations when switching.
@nl
P2093
P1476
Loss of response after switchi ...... considerations when switching.
@en
P2093
Howard C Margolese
Julie Eve Desmarais
Linda Beauclair
P304
P356
10.1097/YIC.0B013E328337910B
P577
2010-05-01T00:00:00Z